Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.
Seema S. Kantak
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Research Funding - Nektar Therapeutics
Steve Lee
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Murali Addepalli
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Ute Hoch
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Rhoneil Pena
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Yolanda Kirksey
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Deborah H. Charych
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Stephen K. Doberstein
Employment or Leadership Position - Nektar
Stock Ownership - Nektar